Sichuan Kelun-Biotech Biopharmaceutical completed a placing of 5.918 million new H shares at a placing price of HK$331.8 per H share. The total net proceeds of the placing is approximately HK$1.943 billion (approximately $250 million).
Kelun-Biotech is a biopharmaceutical company that focuses on the research and development, manufacturing, commercialization of and global collaboration of innovative biological drugs and small molecule drugs.
S&C acted as Hong Kong and U.S. counsel to the joint sponsors and underwriters in Kelun-Biotech’s initial public offering and listing on the Hong Kong Stock Exchange in 2023. Since then, S&C has continuously acted as Hong Kong counsel for Kelun-Biotech.
The S&C team advising Kelun-Biotech was led by Gwen Wong and Ching-Yang Lin. The core team consisted of Tracy Li, Mengli Wan and Yue Li.